January 18, 2018 11:57 PM ET

Biotechnology

Company Overview of Merrimack Pharmaceuticals, Inc.

Executive Profile

Douglas A. Lauffenburger

Member of Scientific Advisory Board, Merrimack Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 7 Board Members in 7 organization across 8 different industries.

See Board Relationships
----

Background

Dr. Douglas A. Lauffenburger, also known as Doug, Ph. D., serves as Director of Biological Engineering Division of Massachusetts Institute of Technology (MIT) and its Co-Director of Bioengineering & Environmental Health. Dr. Lauffenburger has served as Consultant of Astra-Zeneca, CellPro, Entelos, Inc., Insert Therapeutics, Inc., Johnson & Johnson, Pfizer, SyStemix, the Burroughs-Wellcome Foundation and the Whitaker Foundation. His expertise spans multiple disciplines ...

Corporate Headquarters

One Kendall Square
Cambridge, Massachusetts 02139

United States

Phone: 617-441-1000
Fax: --

Board Members Memberships

There is no Board Members Memberships data available.

Education

PhD
University of Minnesota
BS 1975
University of Illinois-Urbana-Champaign

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John F. Thero Chief Executive Officer, President and Director
Amarin Corporation plc
$575.3K
Adelene Q. Perkins Chairman & CEO
Infinity Pharmaceuticals, Inc.
$668.8K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals, Inc.
$689.2K
Charles J. Link Jr., M.D.Co-Founder, Chairman, CEO & Chief Scientific Officer
NewLink Genetics Corporation
$714.9K
Saeed Motahari President, CEO & Director
INSYS Therapeutics, Inc.
--
Compensation as of Fiscal Year 2016.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Merrimack Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.